LLY vs BMY
By Alex · Tickerpine
Eli Lilly and Company vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BMY |
|---|---|---|
| Price | $1,273.46 | $61.48 |
| Market cap | $1.14T | $125.59B |
| P/E ratio | 42.7 | 13.5 |
| ROE | 102.29% | 46.60% |
| Profit margin | 33.53% | 18.87% |
| Revenue growth | 47.70% | 5.70% |
| Dividend yield | 0.54% | 4.10% |
| Beta | 0.45 | 0.18 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BMY in plain English
- LLY is the bigger company — about 9.0× the market cap of BMY.
- BMY is cheaper on earnings (P/E 13.5 vs 42.7).
- LLY earns a higher return on equity (102% vs 47%).
- LLY is growing revenue faster (48% vs 6%).
- BMY has the higher dividend yield (4.10% vs 0.54%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.